预约演示
更新于：2026-09-30
Ropivacaine Hydrochloride
盐酸罗哌卡因
更新于：2026-09-30
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H29ClN2O2 |
InChIKeyVSHFRHVKMYGBJL-CKUXDGONSA-N |
CAS号132112-35-7 |
关联
3,197
项与 盐酸罗哌卡因 相关的临床试验CTRI/2025/07/091951
To compare the efficacy of Hyperbaric Ropivacaine vs Isobaric Ropivacaine in Thoracic segmental spinal anaesthesia in Percutaneous Nephrolithotomy Surgery - NIL
ChiCTR2600125462
Effects of bupivacaine liposome versus ropivacaine hydrochloride on postoperative pain and recovery quality in patients undergoing robotic-assisted radical prostate cancer resection
NCT07839039
A Pilot Study Comparison of Postoperative Analgesia Using Two Modes of Local Anesthetic Epidural Delivery After Bladder Exstrophy Repair: Programmed Intermittent Bolus Versus Continuous Infusion
100 项与 盐酸罗哌卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的专利（医药）
登录后查看更多信息
2,007
项与 盐酸罗哌卡因 相关的文献（医药）2026-09-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Structural characterization and enhanced analgesic efficacy of a bio-responsive lyotropic liquid crystal Quject® gel for long-acting ropivacaine delivery
Article
作者: Kim, Hyung Chul ; Baik, Hye Jung ; Lim, Duck Soo ; Jeong, Seong Hoon ; Maharjan, Ravi ; Lim, Ji Hyang
The effective management of acute postoperative pain remains challenging, primarily owing to the short half-life and rapid systemic clearance of anesthetics. Therefore, this study aims to report structural characterization, pharmacokinetic profiling, and enhanced analgesic efficacy of a bioresponsive lyotropic liquid crystal Quject® gel for long-acting ropivacaine delivery. A lipid system of lecithin, Span 20, and tocopherol acetate, was systematically optimized via ternary phase diagram to identify formulations that transition from sol-to-gel upon contact with biological fluids. Structural characterization using SAXS and cryo-TEM confirmed the formation of a stable reversed hexagonal phase (lattice constant a≈5.80 nm; characteristic Bragg peaks at q≈0.80, 1.38, and 1.60 nm⁻1 with 1:√3:√4 ratio). The dense nanochannels of the hexagonal depot restricted ropivacaine diffusion, resulting in a minimal initial burst (Day-0: 3.80%) and 43.66% cumulative drug release by Day-7, compared to near-complete release (≥95%) from lamellar controls over the same period. In vivo pharmacokinetic analysis in rats revealed a 7-fold increase in elimination half-life (t1/2: 5.98vs. 0.81-h) and a 4-fold reduction in peak plasma concentration (Cmax: 58.13 vs. 231.00 ng/mL) compared to those of ropivacaine HCl, substantially mitigating systemic toxicity risk. The tlast concentration extended to 42-h, encompassing the critical 48-h postoperative recovery period. Furthermore, the von Frey test in a rat incision model confirmed sustained analgesic efficacy for up to 72-h after a single subcutaneous administration compared to ropivacaine HCl (≤6-h). These findings establish a direct structure-pharmacokinetics-efficacy relationship within Quject® gel, offering scalable, biocompatible prolonged postoperative analgesia.
2026-07-01ACTA ANAESTHESIOLOGICA SCANDINAVICA
Effect of Ultrasound‐Guided Lateral Infraclavicular Brachial Plexus Block With Lidocaine or Ropivacaine for Closed Reduction of Distal Radius Fractures: A Randomized Controlled Noninferiority Trial
Article
作者: Rothe, Christian ; Knudsen, Rasmus Linnebjerg ; Thomsen, Jens Haavig ; Lange, Kai Henrik Wiborg ; Piosik, Zofia ; Lundstrøm, Lars Hyldborg ; Bahuet, Aurelien‐Xuan Rosendal ; Kaaber, Peter Bak ; Nørskov, Anders Kehlet ; Pisljagic, Sanja ; Harwood, Cecilie Dupont ; Steensbæk, Mathias Therkel ; Bjulf, Rikke Helene Frølund ; Jellestad, Anne‐Sofie Linde ; Yousef, Sina
ABSTRACT:
Background:
Closed reduction of distal radius fractures is painful, and current analgesic strategies may be inadequate. Ultrasound‐guided lateral infraclavicular brachial plexus block may offer complete analgesia and muscle relaxation, potentially improving patient comfort and reduction quality. However, benefits and challenges regarding anesthetic agents for this procedure remain unclear.
Methods:
In this randomized, controlled, blinded, noninferiority trial, 63 adults with distal radius fractures requiring closed reduction received a lateral infraclavicular block with either 30 mL of ropivacaine 0.5%, lidocaine 1% with epinephrine, or ropivacaine 0.2%. The primary outcome was block success at 45 min, defined as complete sensory and extensive motor block of the radial, musculocutaneous, ulnar, and median nerves. Noninferiority was assessed using a margin of 20%. Exploratory outcomes included sensory and motor block assessments, time to pain relief, block duration, pain during reduction, patient satisfaction, quality of closed reduction, fracture treatments, and safety.
Results:
Ropivacaine 0.2% was statistically inferior to ropivacaine 0.5% in achieving block success at 45 min (risk ratio (RR) 0.63, 97.5% CI 0.40–0.99). Lidocaine 1% with epinephrine did not meet the predefined noninferiority criteria for block success (RR 0.95, 97.5% CI 0.73–1.22) but did provide comparable analgesia with a shorter block duration. Pain scores during reduction were low across all groups, with a significant decrease in pain from baseline. Patient satisfaction was high in all groups. No significant differences were found in the quality of closed reduction, safety, or fracture treatments.
Conclusion:
Lateral infraclavicular block with ropivacaine 0.2% failed to demonstrate noninferiority for block success and was statistically inferior to ropivacaine 0.5%. Inferiority testing should be interpreted cautiously within the context of a noninferiority design, although the results suggest reduced effectiveness for distal radius fracture reduction. Lidocaine 1% with epinephrine yielded inconclusive results for noninferiority on block success, but provided a shorter block duration without compromising analgesia, patient satisfaction, or quality of reduction.Trial Registration:ClinicalTrials.gov
Identifier NCT06379490 (released April 23, 2024);
https://clinicaltrials.gov/study/NCT06379490;
EUCT Identifier 2024–510,572–20‐00;
https://euclinicaltrials.eu/ctis‐public/view/2024‐510572‐20‐00
2026-05-01INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA
Median effective dose (ED50) of intrathecal ropivacaine for labor analgesia initiation in nulliparous vs. multiparous women: an up-down sequential allocation study
Article
作者: Yan, Zhi-Rong ; Zhang, Long-Xin ; Zhang, Su-Jing ; Liu, Ming ; Xiao, Pei-Han ; Miao, Li-Yan ; Huang, Yu ; Chen, Xiao-Fen
BACKGROUND:
Extensive research has investigated the median effective dose of local analgesics for labor analgesia in nulliparous women, whereas studies on multiparous women remain limited. This study aimed to determine and compare the intrathecal ropivacaine median effective dose for labor analgesia between multiparous and nulliparous women.
METHODS:
Thirty nulliparous and thirty multiparous women were enrolled and divided into two groups. All participants received combined spinal-epidural analgesia for labor pain management.This study employed an up-down sequential allocation design.The first participant received 3.0 mg of ropivacaine intrathecally. Subsequent doses were adjusted in 0.3 mg increments or decrements using an up-down sequential allocation protocol. Effective analgesia was defined as achieving a numerical rating scale score ≤3 within 10 min after intrathecal administration. The Dixon and Massey sequential method and Probit regression were applied to calculate the median effective dose of intrathecal ropivacaine in both groups.
RESULTS:
The median effective dose for intrathecal ropivacaine was 1.62 mg (95% confidence interval, 0.99-1.89 mg) in nulliparous women and 2.16 mg (95% confidence interval, 1.32-2.52 mg) in multiparous women, with a significant between-group difference.
CONCLUSIONS:
The median effective dose of intrathecal ropivacaine for labour analgesia is greater in multiparous than in nulliparous women during spontaneous latent phase labor.
100 项与 盐酸罗哌卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 产痛 | 澳大利亚 | 2013-02-27 | |
| 术后疼痛 | 日本 | 2001-04-04 | |
| 急性疼痛 | 奥地利 | 1996-04-22 | |
| 急性疼痛 | 比利时 | 1996-04-22 | |
| 急性疼痛 | 法国 | 1996-04-22 | |
| 急性疼痛 | 德国 | 1996-04-22 | |
| 急性疼痛 | 爱尔兰 | 1996-04-22 | |
| 急性疼痛 | 意大利 | 1996-04-22 | |
| 急性疼痛 | 卢森堡 | 1996-04-22 | |
| 急性疼痛 | 荷兰 | 1996-04-22 | |
| 急性疼痛 | 英国 | 1996-04-22 | |
| 麻醉 | 奥地利 | 1996-04-22 | |
| 麻醉 | 比利时 | 1996-04-22 | |
| 麻醉 | 法国 | 1996-04-22 | |
| 麻醉 | 德国 | 1996-04-22 | |
| 麻醉 | 爱尔兰 | 1996-04-22 | |
| 麻醉 | 意大利 | 1996-04-22 | |
| 麻醉 | 卢森堡 | 1996-04-22 | |
| 麻醉 | 荷兰 | 1996-04-22 | |
| 麻醉 | 英国 | 1996-04-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 股神经病 | 临床3期 | 中国 | 2025-07-03 | |
| 腹股沟疝 | 临床3期 | - | 2025-04-01 | |
| 镇痛 | 临床3期 | 中国 | 2023-03-21 | |
| 拇囊炎 | 临床3期 | 美国 | 2023-03-13 | |
| 肛瘘 | 临床2期 | 中国 | 2026-04-20 | |
| 拇外翻 | 临床2期 | 美国 | 2019-03-05 | |
| 疼痛 | 临床阶段不明 | 法国 | 2009-03-01 | |
| 神经阻滞 | 临床前 | 中国台湾 | 2024-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 50 | 淵選夢獵構襯襯齋選繭(築觸積遞選繭糧醖餘餘) = 繭醖獵簾艱艱醖簾夢窪 膚繭憲築糧醖願鬱鹽選 (憲窪糧願繭構網鹽艱鹽 ) 更多 | 积极 | 2026-09-24 | |||
淵選夢獵構襯襯齋選繭(築觸積遞選繭糧醖餘餘) = 壓積鏇選窪獵範積網壓 膚繭憲築糧醖願鬱鹽選 (憲窪糧願繭構網鹽艱鹽 ) 更多 | |||||||
临床3期 | 63 | 鹹鏇鬱築糧構壓範醖衊(積範遞齋淵憲艱觸顧醖): RR = 0.95 (97.5% CI, 0.73 ~ 1.22) 更多 | 不佳 | 2026-07-01 | |||
Lidocaine 1% with epinephrine | |||||||
N/A | 287 | (Locoregional Analgesia by Femoral Triangle Catheterization) | 壓繭簾網繭蓋願選製壓 = 鬱夢遞壓鹽衊範醖廠淵 齋壓窪齋淵淵選獵獵願 (鏇襯顧廠鏇觸遞構衊壓, 膚構遞觸窪鬱膚鏇願遞 ~ 觸觸顧廠觸齋鑰糧齋餘) 更多 | - | 2026-06-12 | ||
(Tissue Infiltration) | 壓繭簾網繭蓋願選製壓 = 簾願窪鹽鹽顧簾蓋鏇鬱 齋壓窪齋淵淵選獵獵願 (鏇襯顧廠鏇觸遞構衊壓, 獵糧鏇糧憲鑰壓繭鏇醖 ~ 範選憲膚鏇顧壓襯顧願) 更多 | ||||||
临床3期 | 60 | 窪夢壓艱膚窪獵淵顧繭(餘積蓋膚簾構選蓋淵襯) = 鹽壓淵簾選觸網鑰壓獵 廠鹽獵網獵窪觸醖壓網 (廠鏇窪艱壓襯獵淵構艱 ) 更多 | 积极 | 2026-06-01 | |||
窪夢壓艱膚窪獵淵顧繭(餘積蓋膚簾構選蓋淵襯) = 鏇選繭構夢窪衊鹹糧鏇 廠鹽獵網獵窪觸醖壓網 (廠鏇窪艱壓襯獵淵構艱 ) 更多 | |||||||
临床4期 | 240 | (Continuous Infusion) | 構衊簾壓蓋簾衊餘鹽鹹(鏇窪糧鏇選鏇齋襯遞壓) = 鬱艱衊顧繭齋鑰廠網遞 鑰築繭憲觸選簾憲網鬱 (範醖鹹網廠鹹膚範積構, 56.3) 更多 | - | 2026-05-13 | ||
(Intermittent Bolus) | 構衊簾壓蓋簾衊餘鹽鹹(鏇窪糧鏇選鏇齋襯遞壓) = 膚網夢膚窪築鹽壓積艱 鑰築繭憲觸選簾憲網鬱 (範醖鹹網廠鹹膚範積構, 55) 更多 | ||||||
临床3期 | 34 | continuous erector spinae block (ESB)+Ropivacaine (Continuous Erector Spinae Block) | 膚鹽選獵鑰壓糧鹽簾築(構顧齋顧遞鹽範觸遞簾) = 願壓繭網構廠襯繭觸糧 壓願壓簾憲築窪壓衊觸 (壓網鹽糧衊範鹽憲觸淵, 醖顧鏇顧鬱獵淵築淵齋 ~ 夢蓋鏇憲觸鬱簾餘顧壓) 更多 | - | 2026-05-13 | ||
continuous paravertebral block (PVB)+Ropivacaine (Continuous Paravertebral Block) | 膚鹽選獵鑰壓糧鹽簾築(構顧齋顧遞鹽範觸遞簾) = 遞鏇鏇築廠蓋廠夢醖積 壓願壓簾憲築窪壓衊觸 (壓網鹽糧衊範鹽憲觸淵, 範鬱觸醖餘鑰壓憲顧遞 ~ 構網糧齋鑰簾壓網糧鏇) 更多 | ||||||
早期临床1期 | 60 | (Nulliparous women) | 膚蓋製遞鏇齋鹽構鑰鏇(衊窪衊壓蓋遞醖選憲簾) = 積獵醖獵餘鬱築淵夢願 膚範鹽鬱顧衊壓選願獵 (夢膚衊獵遞顧願構繭積, 0.99 ~ 1.89) | 积极 | 2026-05-01 | ||
(Multiparous women) | 膚蓋製遞鏇齋鹽構鑰鏇(衊窪衊壓蓋遞醖選憲簾) = 齋艱遞廠鹹夢衊鹹遞襯 膚範鹽鬱顧衊壓選願獵 (夢膚衊獵遞顧願構繭積, 1.32 ~ 2.52) | ||||||
临床4期 | 50 | (Group 1: Ropivacaine Plus Dexamethasone) | 鏇願醖製選餘蓋顧蓋夢(積餘鏇廠衊積範製願衊) = 鑰鏇鹽網積廠淵築醖選 醖簾鹹簾壓艱鹽鏇齋蓋 (鏇膚顧淵艱衊鑰構襯鏇, 1.6) 更多 | - | 2026-04-27 | ||
Placebo+Dexamethasone (Group 2: Placebo Plus Dexamethasone) | 鏇願醖製選餘蓋顧蓋夢(積餘鏇廠衊積範製願衊) = 觸觸蓋壓鹽願獵糧膚網 醖簾鹹簾壓艱鹽鏇齋蓋 (鏇膚顧淵艱衊鑰構襯鏇, 2.1) 更多 | ||||||
临床4期 | 76 | 獵艱遞鏇網願範鹹壓鬱(蓋遞窪築簾網製憲淵顧) = 鬱簾簾廠膚鹹顧廠廠廠 遞築齋獵襯糧餘壓築鬱 (鏇淵遞糧淵願窪簾艱艱, 3.0) 更多 | 不佳 | 2026-03-01 | |||
Placebo (normal saline) | 顧齋齋餘襯窪廠餘壓繭(顧築觸築製觸鬱齋膚窪) = 醖廠積醖範顧窪網憲憲 鬱網願壓衊窪願醖鬱壓 (糧壓廠餘窪製醖積衊願 ) 更多 | ||||||
临床4期 | 83 | pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Non Opioid, Multimodal Protocol) | 夢簾衊壓壓鏇鏇膚獵獵(廠製壓膚艱蓋壓構憲廠) = 鏇範齋蓋蓋鹽獵壓鏇鏇 廠鏇膚齋醖鹹艱觸積鹽 (繭構糧簾糧襯願壓築鹹, 1.7) | - | 2026-02-10 | ||
pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Opioid Protocol) | 夢簾衊壓壓鏇鏇膚獵獵(廠製壓膚艱蓋壓構憲廠) = 製廠壓蓋壓遞醖蓋鹽觸 廠鏇膚齋醖鹹艱觸積鹽 (繭構糧簾糧襯願壓築鹹, 1.6) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用